NCT06851611View on ClinicalTrials.gov

The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
COVID19, Sars-Cov-2
Interventions
BIOLOGICAL

COVID-19 vaccine, low dose level

Test article

BIOLOGICAL

COVID-19 vaccine, high dose level

Test article

OTHER

Nasal Drops

Method of administration of test article

OTHER

Nasal Spray

Method of administration of test article

Trial Locations (1)

70210

RECRUITING

Kuopio University Hospital, Kuopio

All Listed Sponsors
lead

Rokote Laboratories Finland Oy

INDUSTRY